TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Any Infections or Any Grade 3/4 Infections Through Week 24
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Duration of Infections Through Week 24
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Simple Shoulder Test (SST) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Afebrile Neutropenic Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients experiencing adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Vascularity rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Color of burn scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Patients Showing a Presence of Methylated Tumor Suppressor Genes Achieving Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Degree of Demethylation in Patient Tumor Tissue Induced by 5-azacitidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: percentage of patients whose wound heals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac arrest or bradyarrhythmias
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of Intraocular pressure at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of aqueous flow at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of uveoscleral outflow at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of trabecular outflow facility at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of acute febrile cases with favorable clinical outcomes at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinic Attachment Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subgingival Plak Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Release of high sensitivity Troponin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Asthma Control Questionnaire-6 (ACQ-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in siSBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parent Awareness of Own Emotion Score for Sadness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Emotion Regulation Using the Emotion Regulation Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of Disruptive Behaviors Using the Eyberg Child Behavior Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To The First Breakthrough Overt HE Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum regucalcin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver fibrosis levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS injury at term
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients with normal median value of serum total testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax of Digoxin, Rosuvastatin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Digoxin, Rosuvastatin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLr of Digoxin, Rosuvastatin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose AUC after OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of malnutrition phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: acute improvement in respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: absence of adverse events related to stimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Biliary complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6 Minute Walk Test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rate of perceived exhaustion (RPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10 meter walk test gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrences of pericarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Filter life time of continuous renal replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Freedom From Major Adverse Cardiac Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Procedural Success (Residual Stenosis <50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained Effects in Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retinal vessel diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-epithelialization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain intensity measured by the composite pain index (CPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participant-reported pain episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gleason score correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain-free Walking Distance After Period 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free Walking Distance After Period 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free Walking Distance After Period 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free/recurrence-free interval
Endpoint domain: Mortality/survival
Primary endpoint: Major Adverse Cardiac Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reproductive hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Gestational Diabetes Mellitus (GMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of preterm birth (before 37 weeks gestation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of Patients Responding to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of vaccine related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Exclusive breastfeeding among children 0-6 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Child heights and weights (children 24-60 months of age)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complementary feeding for children 6-23.9 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Diagnostic performance of deltaI ITV / delta RR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication frequency (infectious complications)
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality from severe pneumonia by 7th day of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Change in moderate and vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical status in COPD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to service disengagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: End tidal volatile anesthetic concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior Chamber Cell Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incorrect placement of guide pin
Endpoint domain: Adverse events/effects
Primary endpoint: Number of X-ray exposures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: X-ray exposure time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Blood glucose response to test meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reported satiety in response to test meal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reported sensory and textural rating of test meal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tampa Kinesiophobia Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Haemophilia Adult Health-Related Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Confirmation of diagnosis by pathologist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vegetable and fruit intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Total Fluid Cognitive Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours (AUC[0-48])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC[0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of AUC Obtained by Extrapolation (%AUC[inf,ex])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemotherapy related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of women with complete clinical information on post-abortion status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short and long term neonatal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Brain Tissue Pulsatility (BTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in days substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quantity of marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICD therapies for ventricular arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraocular pressure lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Weighted-mean 24-hour Serial FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nasal Obstruction Symptom Evaluation (NOSE) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression free survival (modified RECIST or RECIST 1.1)
Endpoint domain: Mortality/survival
Primary endpoint: Slope of PRA increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement of semantic performances
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of symptomatic respiratory infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rates of vomiting and retching
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of Trans-epidermal Water Loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Concentration of thermolabile proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity level of thermolabile enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of women not meeting the recommended intake for iodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Doravirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-life (t1/2) of Plasma Doravirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D-5L questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hand grip dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial High Rate Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procalcitonin levels in VAP vs Non-VAP cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of urinary incontinence episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Subjective score of suspicion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative deformity correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response assessed by a change in HBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response as assessed by a change in SCCAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response as assessed by a change in PROMIS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical response as assessed by a change in QOL questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Yale-Brown Obsessive Compulsive Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Clinical Global Impression of Change Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change in 6-minute Walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood NT-proBNP Level on 3 Days after Random Allocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of Change from Baseline Blood NT-proBNP Level on 5 Days after Random Allocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immunogenicity of evaluated vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of evaluated vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Weighted-mean 24 Hour Serial FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with Hemodynamic Instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetics of 1-MNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of 1-MNA
Endpoint domain: Adverse events/effects
Primary endpoint: Catecholamine metabolism and blood cell adenylate cyclase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the 21-item Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reading speed day 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reading speed M3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomarkers of type 2 diabetes risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovery according to diagnostic criteria for LE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in plasma mtDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validation of SQOL-6D
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Liver Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proinflammatory cytokine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Survival and Non-relapse Mortality at Day +200
Endpoint domain: Mortality/survival
Primary endpoint: acute and late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: plasma markers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of insulin requirement by ≥ 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in Glucagon stimulated C - peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of beta cell function via hyperglycemic clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hand Hygiene Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in absorption of TMC435
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in absorption of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in absorption of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in movement error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Voluntary Isometric Contraction (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle Activation of Upper Trapezius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cervical Range of Motion (CROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in mean Numeric Rating Scale (NRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytochrome Oxidase/Citrate Synthase (COX/CS) Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to virologic rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude/ durability of increases in absolute CD4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean % change in fasting LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Adverse Events Related to Sexual Function
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of early postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Comparative bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical excitability (post to pre treatment) mean difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Upper limb motor performance (post to pre treatment) mean difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Reported a Clinical Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Reported a Laboratory Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical status at day 120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite clinical endpoint of all death, all MI and all revascularizations
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of participants achieving two consecutive ≥30% reductions in iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Swollen Joint Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intraocular Pressure at Week 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes